BridgeBio Oncology Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Pedro Beltran's CEO employment agreement (retroactive April 20, 2026) sets base salary at $670,000 and target bonus at 55% of base. Idan Elmelech's COO agreement (same effective date) sets base salary at $515,000 and target bonus at 40% of base; both executives participate in the Executive Severance Plan as Tier 1 and Tier 2 respectively. Dr. Eli Wallace entered into a 12-month consulting agreement (effective April 21, 2026) to advise on R&D programs, with compensation via continued vesting of existing equity grants. Amendment No. 9 to the Transition Services Agreement (June 23, 2026) updated service schedules with redacted details.
Why this rating
Executive compensation formalization is standard corporate housekeeping; CEO + COO combined salary ~$1.185M is ~0.26% of $465M market cap. Consultant and TSA amendment are routine.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.